Anthony Coles - Regeneron Pharmaceuticals Independent Director
| REGN Stock | USD 893.99 7.20 0.80% |
Director
Dr. N. Anthony Coles, M.D., is Independent Director of the Company. has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer, and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck Co., Inc., BristolMyers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., and CRISPR Therapeutics AG. Dr. Coles was a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors. since 2017.
| Age | 57 |
| Tenure | 7 years |
| Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
| Phone | 914 847 7000 |
| Web | https://www.regeneron.com |
Regeneron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 203.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Wayne Tatro | Provident Bancorp | 72 | |
| Frank Cousins | Provident Bancorp | 55 | |
| David Herndon | Home Federal Bancorp | 79 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Jay Gould | Provident Bancorp | N/A | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Richard Peeke | Provident Bancorp | 69 | |
| Mari Cano | Betterware De Mexico | N/A | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| John Bosen | Provident Bancorp | 49 | |
| Mark Harrison | Home Federal Bancorp | 58 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 |
Regeneron Pharmaceuticals Leadership Team
Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Baker, Independent Director | ||
| Joseph Goldstein, Independent Director | ||
| Anthony Coles, Independent Director | ||
| Patrice Gilooly, Senior Operations | ||
| Christopher CPA, Head Finance | ||
| George Sing, Independent Director | ||
| Gerald Underwood, Senior Operations | ||
| Peter Powchik, Senior Vice President - Clinical Development | ||
| Jay Markowitz, Senior Vice President - Portfolio Management | ||
| Robert Terifay, Sr. VP of Commercial | ||
| Robert Landry, CFO and Sr. VP of Fin. | ||
| Michael Brown, Independent Director | ||
| Ryan Crowe, Senior Analysis | ||
| Christine Poon, Independent Director | ||
| Neil Stahl, Executive VP of RandD | ||
| Marion McCourt, Senior Vice President and Head of Commercial | ||
| George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director | ||
| Andrew Murphy, Executive Research | ||
| Huda Zoghbi, Director | ||
| Bonnie Bassler, Director | ||
| Joseph LaRosa, Senior Vice President General Counsel, Secretary | ||
| Bob McCowan, Senior Officer | ||
| Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply | ||
| Leonard Schleifer, President CEO, Director | ||
| Alfred Gilman, Independent Director | ||
| Roy Vagelos, Chairman of the Board | ||
| Michael Aberman, Vice President - Strategy | ||
| Manisha Narasimhan, IR Contact | ||
| Douglas McCorkle, Vice President Controller, Assistant Treasurer | ||
| Marc TessierLavigne, Independent Director | ||
| Christopher Fenimore, Vice President Controller | ||
| Arthur Ryan, Independent Director |
Regeneron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 88.03 B | ||||
| Shares Outstanding | 107.94 M | ||||
| Shares Owned By Insiders | 2.58 % | ||||
| Shares Owned By Institutions | 89.27 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | 15.51 X |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.78 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.